Comparative Pharmacology
Head-to-head clinical analysis: MAREZINE versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAREZINE versus PROMETHAZINE HYDROCHLORIDE.
MAREZINE vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Marezine (cyclizine) is a piperazine-derivative histamine H1-receptor antagonist with central anticholinergic and antiemetic activity. It competitively blocks H1 receptors in the vestibular apparatus and the chemoreceptor trigger zone (CTZ), suppressing nausea and vomiting. It also has antimuscarinic effects on the vomiting center.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
50 mg intramuscularly or intravenously every 4 to 6 hours as needed for motion sickness; 50 mg orally 30 to 60 minutes before travel, then every 4 to 6 hours up to 150 mg/24h.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults; prolonged to 8-12 hours in elderly or hepatic impairment
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Renal: 70-80% as unchanged drug and metabolites; fecal: ~20%; biliary: minor
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic